Risk biomarkers for estrogen receptor (ER)-negative breast cancer have clear value for breast cancer prevention. We previously reported a set of lipid metabolism (LiMe) genes with high expression in the contralateral unaffected breasts (CUBs) of ERnegative cancer cases. We now further examine LiMe gene expression in both tumor and CUB, and investigate the role of Pre-B-cell leukemia homeobox-1 (PBX1) as a candidate common transcription factor for LiMe gene expression. mRNA was extracted from laser-capture microdissected epithelium from tumor and CUB of 84 subjects (28 ER-positive cases, 28 ERnegative cases, 28 healthy controls). Gene expression was quantitated by qRT-PCR. Logistic regression models were generated to predict ER status of the contralateral cancer. Protein expression of HMGCS2 and PBX1 was measured using immunohistochemistry. The effect of PBX1 on LiMe gene expression was examined by overexpressing PBX1 in MCF10A cells with or without ER, and by suppressing PBX1 in MDA-MB-453 cells. The expression of DHRS2, HMGCS2, UGT2B7, UGT2B11, ALOX15B, HPGD, UGT2B28 and GLYATL1 was significantly higher in ER-negative versus ER-positive CUBs, and predicted ER status of the tumor in test and validation sets. In contrast, LiMe gene expression was significantly lower in ER-negative than ER-positive tumors. PBX1 overexpression in MCF10A cells up-regulated most LiMe genes, but not in MCF10A cells overexpressing ER. Suppressing PBX1 in MDA-MB-453 cells resulted in decrease of LiMe gene expression. Four binding sites of PBX1 and cofactor were identified in three lipid metabolism genes using ChIP-qPCR. These data suggest a novel role for PBX1 in the regulation of lipid metabolism genes in benign breast, which may contribute to ER-negative tumorigenesis.
An understanding of the distinct biology that favors estrogen receptor (ER)-negative versus ER-positive breast cancer will enable the development of strategies to identify women at risk for ER-negative disease and strategies to prevent this subtype cancer. The contralateral unaffected breast (CUB) of women undergoing surgical therapy for newly diagnosed unilateral breast cancer is an efficient model for discovery of subtype-specific risk markers, since studies of metachronous contralateral breast cancer suggest that second primary tumors in the contralateral breast tend to resemble the ER status of the index primary, [1] [2] [3] [4] rendering these women ideal candidates for studies of ER-specific breast cancer risk.
In a previous study, we examined gene expression in random fine needle aspirates (rFNA) of the CUB of newly diagnosed breast cancer patients and identified a highly significant lipid metabolism (LiMe) gene signature in CUBs, which was expressed at higher levels in women with ERnegative tumors. 5 These results suggested that the LiMe gene signature may identify women at risk for ER-negative disease. Given the striking degree of co-expression of this gene set in both the discovery and validation sets of our previous study, we performed a bioinformatic analysis of LiMe gene promoter regions, looking for a master regulator of these genes. This pointed to PBX1, a member of three amino acid loop extension (TALE) family of homeodomain proteins, [6] [7] [8] [9] [10] as a candidate master regulator of the LiMe gene signature, which may therefore contribute to the genesis of ER-negative breast cancer. Although PBX1 has previously been identified as a pioneer factor that drives ER signaling by remodeling the chromatin and increasing DNA accessibility in breast cancer, 11, 12 with a role as an upstream initiator of ER-mediated signaling, this study was performed in the ER-positive breast cancer cell line MCF7, and its role in breast cells lacking ER has not been studied. In this context, it is important to note that ER-positive cells are rare in morphologically normal breast, 13 where the proliferative effects of ER signaling are paracrine. 14 In the present report we describe validation of the finding that LiMe gene expression is enriched in the CUBs of women with ER-negative breast cancer. Upon comparison of LiMe gene expression in benign CUB epithelium to matched tumors, we observed an unprecedented reversal of gene expression patterns in ER-negative tumors and their matched CUBs. Further, we examined the expression of PBX1 in the benign breast cell line, MCF10A, with or without ER to define alternative functions of PBX1 in the ERpoor environment of the morphologically normal breast.
Material and Methods

Tissue samples
We recruited patients diagnosed with unilateral breast cancer proceeding to contralateral prophylactic mastectomy at the Prentice Women's Hospital of Northwestern Medicine under an approved protocol (NU11B04), with exclusions for neoadjuvant treatment, prior endocrine therapy or pregnancy/lactation during the prior 2 years. A group of reduction mammoplasty (RM) patients were also recruited as standard risk controls. The fresh tissues were frozen and stored in liquid nitrogen. Tissue samples from 56 bilateral mastectomy cases (28 ER1 and 28 ER-) and 28 healthy RM controls were used in this study. The ER1 cases, ER-cases and controls were matched by age, race, and menopausal status. The gene expression data from our prior study 5 of 54 cases (28 ER1, 26 ER-) was used to establish logistic regression modeling (described below), in which women undergoing surgery for unilateral breast cancer agreed to rFNA of the CUB in the operating room, at the time of the therapeutic procedure (NU-835-040).
qRT-PCR based TaqMan low density array assays
Histological diagnosis was made on a face shaving of the frozen tissue to identify nonatypical benign breast epithelium for laser capture microdissection (LCM). Atypical hyperplasia was captured by LCM and stored for future analyses. Total RNA was extracted using Trizol and purified using RNeasyPlus Micro Kit (Qiagen). RNA was treated with DNase and checked for integrity using Agilent 2100 Bioanalyzer. Total RNA (100 ng) was reverse transcribed using High Capacity RNA-to-cDNA Master Mix and preamplified for 12 cycles using TaqMan PreAmp Master Mix (Thermo Fisher Scientific). Target genes along with three housekeeping genes (GAPDH, ACTB and HPRT1) were detected by TaqMan low density array (Thermo Fisher Scientific) preloaded in 384-well microfluidic cards. Assays were designed with small amplicons (<100 bp) to enhance detection sensitivity. Real Time PCR reactions were carried out in an Applied Biosystems 7900HT machine for 40 cycles. For each target gene, expression level was normalized against the average expression of three housekeeping genes.
Immunohistochemistry
We evaluated the antibodies that are available for DHRS2 (Aviva), HMGCS2 (Abcam), UGT2B7 (Aviva), ALOX15B (Aviva), ACSL3 (Sigma) and PBX1 (Abnova) using in a test set of tissues (including brain, breast, colon, liver, lung, kidney, pancreas, prostate, skin, spleen, stomach, tonsil). Monoclonal antibodies against human PBX1 (clone 4A2, Abnova) and human HMGCS2 (clone EPR8642, Abcam) showed sufficient sensitivity and specificity and were used to detect protein on formalin-fixed, paraffin-embedded (FFPE) sections from normal breast and breast tumor. The IHC procedure was done using Bond Max by Leica Microsystems and the Polymer Detection System. The intensity of IHC staining of PBX1 (in nuclear) and HMGCS2 (in cytoplasm) was scored on a semiquantitative scale (0 5 absent, 1 5 weak, 2 5 moderate, and 3 5 strong). The IHC score was calculated as the product of intensity (1, 2, or 3) multiplied by percentage of positively staining cells, with a range of 0 to 300. The contralateral breast is the focus of intense interest in breast cancer research. Here the authors find a set of lipid metabolism genes highly expressed in the unaffected breast of women with estrogen (ER)-negative breast cancer. They identify the transcription factor PBX1 as a master regulator controlling expression of these genes in cell line models. Importantly, expression of the lipid metabolism genes predicted ER status of the tumor in the affected breast, implicating metabolic pathways in the genesis of ER-negative breast cancer.
University). The cells were maintained in phenol red-free DMEM/F12 medium supplemented with 5% fetal bovine serum, 20 ng/ml EGF, 5 lg/ml hydrocortisone, 100 ng/ml cholera toxin, and 10 lg/ml insulin. The lentiviral vector (PBX1-Lv105) and Lv105 (empty vector) were obtained from GeneCopoeia and used to infect MCF10A, ERIN, and MDA-MB-231 cells as previously described. 16 The stably infected cells were selected using medium containing 500 ng/ml puromycin. The expression of PBX1 was detected using Western blot and two independent derived colonies with the highest protein expression levels were used to detect LiMe gene expression.
The lentiviral vectors pLenti-H1 with three PBX1-shRNA and scramble shRNA were obtained from Amsbio. The sequences of the PBX1-shRNAs are: PBX1-shRNA1: CGA-CAGAAATCCTGAATGAAT; PBX1-shRNA2: TCGGCTGG TTCTTCCAGTTCT; PBX1-shRNA3: CAGACAGGAGGA-TACAGTGAT. The sequence of the scramble shRNA is GTCTCCACGCGCAGTACATTT. The stably infected cells were selected using medium containing 500 ng/ml puromycin. The expression of PBX1 was detected using Western blot and three independently-derived clones with the lower PBX1 protein expression were used to detect LiMe gene expression.
Chromatin immunoprecipitation (ChIP) assay
The ChIP was performed using Pierce Magnetic ChIP kit according to manufacturer's protocol (Thermo Fisher Scientific). MCF7, MDA-MB-453 and MCF10A-PBX1 cells were cultured to 75-85% confluence. The cells were cross-linked, quenched and lysed. The immunoprecipitation was performed using PBX1 monoclonal antibody clone 4A2 (Abnova) and the purified DNA was quantitated using Qubit. Gene sequences from the list of putative PBX1 biding sites were analyzed using BLAST/BLAT function on Ensemble (http://useast.ensembl.org/). FASTA sequence was exported and primers were ordered from Integrated DNA Technologies. Concentration of DNA was quantitated using Qubit and equal quantity of PBX1 pull down and input DNA was pipetted into each well. qPCR was performed for the binding site and fold enrichment was calculated (DCt 5 Ct target -Ct input, fold enrichment 5 2 (-DCT) ).
Statistical analysis
For patient demographic and clinical information, difference in age and BMI among the three groups (ER1 cases, ERcases and controls) were assessed using ANOVA and differences in menopausal status, race and HER2 status were assessed using v 2 tests. For gene expression analysis in tissue samples and in transfected cells, gene expression was measured by qRT-PCR in triplicates and the means were used for analysis. The target genes were normalized by the housekeeping genes (GAPDH, ACTB and HPRT1). Fold changes were calculated by the average of two clones of PBX1-transfected cells. Pairwise group differences were tested using Wilcoxon rank sum tests with Sidak adjustment for multiple comparisons. The correlation between genes was examined using Pearson correlation test. Logistic regression analysis and receiver operating characteristic (ROC) analysis were performed using different combinations of the expression of multiple genes to establish models discriminating ER subtypes in cancer cases.
Results
Characteristics of the study population
The study population included 84 women, comprising 28 matched triplets of women with ER-positive breast cancer, ER-negative breast cancer and reduction mammoplasty controls. The three groups were balanced for age, menopausal status and race, as shown in Table 1 . ANOVA indicated a significant difference in BMI across the three groups with BMI in the reduction mammoplasty control group (30.0 6 5.8) notably higher than in ER-negative cases (25.3 6 6.3, p 5 0.015), but not significantly higher than in the ER-positive Group (26.7 6 5.5, p 5 0.136). There was no significant difference in HER2 status between ER-positive and ER-negative cases.
Lipid metabolism gene expression in the CUBs differed by the tumor ER status
As a group, LiMe gene expression was higher in CUBs of ER-negative cases compared with the CUBs of ER-positive cases (Fig. 1a ), in agreement with our previous report. 5 A cluster analysis of the 28 samples from standard risk, unaffected women (RM controls) revealed two groups: a group with lower LiMe gene expression, resembling the CUB of ER-positive cases; and a group with higher LiMe gene expression, resembling the CUB of ER-negative cases. More specifically, among the 13 LiMe genes, 8 genes (DHRS2, HMGCS2, UGT2B7, UGT2B11, ALOX15B, HPGD, UGT2B28 and GLYATL1) were significantly higher in CUBs of ER-negative cases compared to the CUBs of ER-positive cases (Fig. 1b) . The other five genes (ACSL3, APOD, GSTT2, SERHL and AKR1B15) did not show significant difference between two groups of CUBs (Supporting Information Fig. 1 ). We then used logistic regression analysis to test whether the LiMe gene expression patterns in the CUBs predicted the ER status of the tumor in the opposite breast. We first used the data from our previous study 5 to establish a logistic regression model to discriminate the ER-negative from ER-positive cases by using ROC analysis. Then, we tested the model using gene expression data from the contralateral breast tissue obtained for the current study (Supporting Information Fig. 2 ). We found that a six-gene regression model (HMGCS2, DHRS2, UGT2B7, UGT2B11, ALOX15B and HPGD) developed using 54 samples from our first study predicted ER status of the contralateral cancer with area under the curve (AUC) value of 0.78 and 95% confidence interval (CI) 0.66 to 0.90 (p 5 0.0042). Using the same regression model, the ROC analysis of 56 tissue samples from the present study confirmed the significant discrimination by ER subtypes, with AUC 5 0.71, 95% CI 0.56 to 0.87, p 5 0.049 (Fig. 1c ).
The pattern of LiMe gene expression is reversed in tumors
In contrast to the CUB results, LiMe gene expression patterns were reversed in the tumors. Specifically, the expression of seven genes (DHRS2, HMGCS2, UGT2B7, UGT2B11, ALOX15B, UGT2B28 and ACSL3) was significantly higher in ER-positive tumor compared to ER-negative tumor ( Fig. 1b and Supporting Information Fig. 1 ). To verify this pattern at the protein level, we used antibodies to PBX1 and HMGCS2, which showed sufficient sensitivity and specificity in the test tissues, for proof-of-principle, to examine patterns of expression in CUB versus tumor samples. We then examined HMGCS2 protein expression using immunohistochemistry in FFPE sections of the matched set of tumor and CUB samples. HMGCS2 showed cytoplasmic positivity, with significantly higher IHC scores in ER-positive tumors than in ER-negative tumors (p < 0.01), but IHC scores were significantly lower in CUB samples from cases with ER-positive tumor compared to CUB samples from cases with ER-negative tumors (p < 0.05) (Fig.  2a , with representative images in Fig. 2b ). Thus the patterns of HMGCS2 expression in CUB versus tumor that were observed by measuring mRNA expression were in agreement with the results of protein expression measured by IHC.
Since most of the published data on gene expression in benign breast tissue from breast cancer patients comes from samples adjacent to the tumor, where expression patterns reflect those seen in the tumor, 17, 18 we examined the pattern of expression of hormone receptor genes (estrogen receptor, progesterone receptor, androgen receptor and prolactin receptor) and other hormone responsive genes 19 in the CUBs and breast cancer samples. As shown in Supporting Information Table 1 , expression of hormone receptors (ESR1, PGR, AR and PRLR) and several estradiol-responsive genes was significantly higher in ER-positive tumor than in ER-negative tumor, but there was no significant difference between the two matching groups of CUBs. A ROC analysis also revealed that the expression of hormone receptors in CUBs did not discriminate samples by tumor ER status (Supporting Information Fig. 3) . Therefore, the pattern of high expression of LiMe genes in CUBs associated with ER-negative cancer is specific for this gene group.
PBX1 as a potential master regulator of lipid metabolism genes
Since this gene set was originally found to show strong within-set correlations, 5 we examined the cross-correlation between individual LiMe genes using Pearson correlation analysis (Supporting Information Table 2 ). This showed that the LiMe genes were most strongly correlated with each other in ER-negative CUB samples, but least correlated in ERpositive tumors. By comparing the CUB data to the tumor data, the within-set correlation was stronger for CUB samples than for tumor samples, suggesting more coordinated expression of this gene set in normal breast than in tumors.
In order to seek a candidate master transcription factor of LiMe genes, bioinformatic analysis of LiMe gene promoter regions was performed using Predicting Associated Transcription factors from Annotated Affinities (PASTAA) 20 and Genomatrix. This revealed several potential transcription factors that may bind the putative binding sites and co-regulate the whole set of LiMe genes, with transcription factor PBX1 ranking the highest (Supporting Information Table 3 ). There are multiple PBX1 and PBX1 co-factor putative binding sites in the promoter regions of the LiMe genes (Supporting Information Table 4 ). We therefore examined PBX1 mRNA expression in tumor and CUB using qRT-PCR (Fig. 3a) and PBX1 protein expression using immunohistochemistry (Fig.  3b, representative images in Fig. 3c ). The patterns of PBX1 The difference in age and BMI among three groups was analyzed by ANOVA with Sidak adjustment on pairwise comparison. The difference in menopausal status and race among three groups were analyzed using v 2 test. The difference in HER2 status between ER1 and ER-group was analyzed using v 2 test. mRNA and protein expression were similar in tumor and in CUB to that observed for the LiMe genes in ER-positive and ER-negative groups; i.e. higher expression in ER-negative CUB than in ER-positive CUB, but lower expression in ERnegative tumor than in ER-positive tumor. These findings are consistent with the notion that PBX1 may be a master regulator of the LiMe gene signature, particularly in benign/normal breast.
PBX1 regulates lipid metabolism gene expression in ER-negative cell lines
We examined several breast cell lines and found PBX1 to be expressed at variable levels in ER-positive and ER-negative cell lines (Supporting Information Fig. 3a) . The ER-negative cell lines, MCF10A and MDA-MB-231 showed endogenous low expression, whereas MDA-MB-453 and SK-BR-3 showed high levels. In ER-positive cell lines, PBX1 was undetectable in BT474, but highly expressed in ZR-75-1, T47D and MCF7. When MCF10A cells were infected with lentiviral vector PBX1-Lv105, two independently-derived colonies with high protein levels of PBX1 (No. 4 and No. 6, as shown in Fig. 4a ) were selected to detect the expression of LiMe genes. The expression of 11 LiMe genes (DHRS2, HMGCS2, HPGD, ALOX15B, UGT2B7, UGT2B11, UGT2B28, GLYATL1, APOD, AKR1B15 and ACSL3) was significantly increased in PBX1-transfected MCF10A cells (Fig. 4b , Supporting Information Cancer Genetics and Epigenetics Table 5 ). There was no significant increase in the expression of hormone receptors (ESR1, PGR, AR and PRLR) by overexpression of PBX1. As a comparison, we also infected MDA-MB-231 cells with PBX1. The expression of six LiMe genes (DHRS2, HMGCS2, UGT2B7, UGT2B11, UGT2B28 and APOD) was significantly increased, but no upregulation of HPGD, ALOX15B, GLYATL1, AKR1B15 and ACSL3 in PBX1-transfected MDA-MB-231 cells (Supporting Information Fig.  4b ), suggesting that PBX1-regulation of some LiMe genes may be limited to benign cells.
The MDA-MB-453 cell line expresses high levels of endogenous PBX1. Therefore, we infected these cells with lentiviral particles containing one of three different PBX1-shRNA, as shown in the methods. Independently-derived clones were selected, and three clones (clone shRNA1-13, clone shRNA2-17, and clone shRNA3-9) showing lower PBX1 protein expression (Fig. 5a ) were used to detect LiMe gene expression. Two clones of scramble shRNA did not show decreases in PBX1. In addition to the significant decrease of PBX1 gene expression, differences in gene expression were also observed in eight LiMe genes (DHRS2, HMGCS2, HPGD, UGT2B7, UGT2B11, UGT2B28, AKR1B15 and GSTT2) when comparing PBX1-shRNA clones to scramble shRNA clones (Fig. 5b) , suggesting the suppression of PBX1 resulted in decreased of LiMe gene expression. However, there were no significant changes in the expression of hormone receptors (ER, PR, AR and PRLR) when PBX1 was inhibited by shRNA.
In order to examine the effects of PBX1 on LiMe gene expression in the presence of ER, we infected MCF10A-ERIN cells with PBX1 and selected two independently-derived colonies with high protein levels of PBX1 (No. 2 and No. 8, Fig.  4a ) to detect LiMe gene expression. In ERIN empty vector (EV) cells, the expression of PBX1 protein remained undetectable as in MCF10A EV cells, i.e. the mere presence of ER did not change PBX1 expression (Fig. 4a) . However, the overexpression of ER did up-regulate the expression of DHRS2, HMGCS2 and HPGD in ERIN cells (Fig. 4c , Supporting Information Table 5) , with no further increase in PBX1-ERIN cells, suggesting a dominant effect of ER on these genes in ERIN cells. Two other genes (UGT2B7 and UGT2B11) also showed increased expression in ERIN cells, but with a further significant increase in PBX1-ERIN cells, suggesting the presence of ER did not interfere with the effects of PBX1 on these two genes. In addition, the expression of UGT2B28 and GLYATL1 was increased by overexpression of PBX1 in ERIN cells. On the other hand, the expression of ALOX15B, APOD, AKR1B15 and ACSL3 (all of which showed up-regulation by PBX1 in MCF10A cells) was not up-regulated by PBX1 in ERIN cells.
Considering the differential effects of PBX1 on the regulation of LiMe gene expression with or without ER, we stratified the CUB samples into four quartiles based on their ER expression levels, and examined the correlation between PBX1 and individual LiMe genes in ER-low samples (first quartile, N 5 14) and in ER-high samples (fourth quartile, N 5 14), respectively. Interestingly, the correlation between PBX1 and LiMe genes was much higher in ER-low CUB samples than in ER-high CUB samples (Supporting Information Table 6 ), consistent with the hypothesis that the effect of PBX1 on LiMe gene expression in benign breast tissues is ER-independent.
PBX1 putative binding sites in promoter regions of LiMe genes
In order to further explore the finding that PBX1 may regulate LiMe genes by directly binding to the promoters of LiMe genes, we identified putative biding sites of PBX1 and its cofactors (MEIS1, HOXA9, HOXC9 ) in the promoter region of LiMe gens using Genomatix (Supporting Information Fig.  5 and Supporting Information Table 7) , and designed 31 pairs of primers to detect the enrichment of DNA immunoprecipitation with a PBX1 antibody. The qPCR results showed that a PBX1-HOX9 binding site located in ACSL3 gene (position 550-566) was enriched in MCF10A-PBX1 cells (Fig. 6a) . In MDA-MB-453 cells, a binding site of homeobox factor HOX was also enriched in ACSL3 gene (position 167-183, Fig. 6b ). In addition, a PBX1-MEIS1 heterodimer binding site was identified in APOD gene (position 147-163) in MCF7 cells (Fig. 6c) . A PBX1 binding site was enriched in HPGD gene (position 36-52) in both MCF7 and MDA-MB-453 cells (Fig. 6d) . These results suggest that PBX1 and its cofactor complex may bind directly to the promoter region of multiple LiMe genes and regulate LiMe gene expression.
Discussion
In this study, we validate our previous observation of increased expression of a group of lipid metabolism genes in the contralateral unaffected breasts of women with ERnegative breast cancer compared to those with ER-positive breast cancer. We present data to support a novel hypothesis that the known pioneer factor PBX1 is a master regulator of this gene set, specifically in ER-low benign breast cells. These findings are strengthened by the fact that our prior study utilized rFNA samples, an epithelium-enriched population, whereas in the present study we used LCM of whole tissue sections to isolate the epithelial fraction, and observed essentially the same results. To further evaluate whether LiMe gene expression in CUBs could be used to predict the ER status of tumors in the affected breast, we used our original data set of CUB rFNA samples to develop a logistic regression model consisting of a six-gene subset of the LiMe genes (DHRS2, HMGCS2, UGT2B7, UGT2B11, ALOX15B and HPGD). This model predicted the ER status of the known Since the LiMe gene set exhibited a high degree of withinset correlation in the discovery set, 5 we examined this further in the current sample set. We observed again that these genes appear to be expressed as a group, with the strongest intraset correlations in CUBs of women with ER-negative breast cancer. Furthermore, in both ER-negative and ER-positive patient groups, within-set correlations were stronger in CUB samples than in tumors. Based on these strong intra-set correlations, we hypothesized the presence of a master regulator of this gene set. Bioinformatics analysis revealed the pioneer factor PBX1 to be a prime candidate for this function. We found increased expression of PBX1 RNA and protein in ERnegative versus ER-positive CUBs, supporting the hypothesis that PBX1 may regulate the expression of LiMe genes. Further evidence for this was provided by overexpressing PBX1 in MCF10A MDA-MB-231 cells and by suppressing PBX1 in MDA-MB-453 cells, which resulted in the predicted changes in LiMe gene expression. Of note, PBX1 has an established role as a pioneer factor in ER-positive breast cancer cells, 11, 12 and our data (in agreement with others 11, 12 ) shows higher expression of both PBX1 and some LiMe genes in ERpositive compared to ER-negative tumors. In reconciling these results, we propose that the LiMe genes as a group may be regulated differently in benign breast tissue than in breast cancer, and that the presence of ER in tumors may subvert the LiMe gene regulatory function of PBX1 to that of ER signaling. Overall, these data show that PBX1 has a significant and consistent positive effect on the expression of 11 out of the 13 lipid metabolism genes that are co-expressed in the CUBs of women with ER-negative breast cancer, and this effect is abrogated by the introduction of ER into MCF10A cells in all but two genes (UGT2B28 and GLYATL1). These results, along with the opposing pattern of gene expression in CUBs and in tumor (discussed below) suggests that regulation of LiMe genes occurs through different mechanisms in benign and malignant tissues, and is influenced by ER expression, possibly mediated by binding with different cofactors. Thus in the benign breast epithelium of women at high risk for cancer, where ER is expressed in a minority of cells, Cancer Genetics and Epigenetics expression of PBX1 may have different consequences than in ER-rich tumors.
PBX1 has a critical role in transcriptional regulation and is involved in a variety of biological processes including cell fate determination during organogenesis as well as oncogenic activity in breast cancer and ovarian cancer. 8, 9 The wellknown function of PBX1 in breast cancer (established in ERpositive cell lines) is that it allows ER to bind to DNA, thereby facilitating estrogen signaling, 11 similar to several other pioneer factors (FOXA1, AP2g and GATA4) in the ERpositive breast cancer cell lines. 21 A recent study reported that PBX1 promoted metastatic progression of ER-positive breast cancer through regulating the ER transcriptional response to epidermal growth factor (EGF) signaling. 12 Thus, PBX1-mediated both ER and EGF signaling in aggressive ERpositive breast cancer. However, LiMe genes were not on the list of the 252 genes in PBX1-mediated EGF pathways. Since we found that PBX1 was also expressed at high level in several ER-negative cell lines, such as MDA-MB-453 and SK-BR-3, it is likely that PBX1 may have other major ER or EGFindependent effects which are not apparent in the presence of ER.
Although the known functions of PBX1 do not shed light on the mechanism whereby it may provide an environment that promotes ER-negative tumorigenesis, possibilities include the regulation of gene transcription by PBX1 through the formation of heterodimeric transcription complexes with HOX and MEIS. 6, 7 Two lipid metabolism genes (HMGCS2 and SERHL) have been identified as PBX1 target genes in an ovarian cancer cell line. 10 In our ChIP-qPCR assays, we found four binding sites for PBX1 and cofactors in three LiMe genes (ACSL3, APOD and HPGD) in three breast cell lines (MCF7, MDA-MB-453 and MCF10A-PBX1). The enrichment difference across cell lines suggests that other factors may interfere in the binding of PBX1 to the target sites. As we only performed ChIP-qPCR on a limited number (31) putative binding sites, we believe there are more unidentified PBX1 binding sites in LiMe genes. Future studies using ChIP-seq will be necessary to seek more PBX binding sites.
The PBX1-HOX heterodimer complex was found to contribute to oncogenic activity in breast cancer.
6,7 HXR9 peptide which targets the interaction between HOX proteins and PBX1 induced apoptosis in breast cancer-derived cell lines.
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PREP1 and MEIS1 competition for PBX1 binding regulates protein stability and tumorigenesis through the Notch signaling pathway. 23, 24 Recently, PREP1 was identified to be a novel epithelial-to-mesenchymal transition (EMT) inducer and pro-metastatic transcription factor in human non-small cell lung cancer cells. 25 We did not find any changes in cell proliferation, invasion and colony formation in PBX1-infected MCF10A and MDA-MB-231 cells (data not shown), suggesting that expression of PBX1 alone is insufficient to promote tumorigenesis. Others have shown that single gene alterations in MCF10A cells can have a modest effect on proliferation and invasion. 26, 27 However, modulation of two genes led to a more tumorigenic phenotype. 28, 29 Thus the interaction of PBX1 with its cofactors needs to be further investigated. Additionally, the role of lipid metabolism is increasingly recognized as important in the genesis of ER-negative breast cancer and has also been reported in the early, preinvasive phase in mouse models where social isolation leads to ERnegative tumors. 30, 31 Although the specific genes differ, the concept of a role for metabolism in early carcinogenesis is similar. Also, further support for the involvement of PBX1 in ER-independent tumorigenesis comes from the finding that a polymorphism in the PBX1 gene is associated with early onset breast cancer, 40 which is more frequently ER-negative. Besides their well-known functions in lipid modification and elimination, transportation and detoxification of different lipid compounds, the lipid metabolism genes also contributed to pathways involved in oncogenes and transcription factors. These include the role of DHRS2 in proto-oncogene c-Myb and p53 stabilization, 32 HMGCS2 in c-Myc-mediated pathways 33 and HPGD regulation by Ets and AP-1 in breast cancer. 34 By using the METABRIC data set, 35 we found that ER-(but not ER1) breast cancer patients carrying gene expression or copy number alterations in DHRS2, UGT2B7, and/or ALOX15B experienced a statistically significant decrease in overall survival, highlighting the specificity of these genes to predict outcomes in ER-cancer patients (Supporting Information Fig. 6 ). The specific roles and interaction of these genes in the genesis of ER-tumors clearly needs further work, but point to a novel role of lipid metabolism abnormalities in the genesis of ER-breast cancer.
Surprisingly, we observed a converse pattern of LiMe gene expression in tumor and CUB when stratified by ER status, with ER-negative tumors having lower expression of several of these genes than ER-positive tumors. This was also supported by corresponding changes in PBX1 mRNA expression and protein expression in PBX1 and HMGCS2. We examined the lipid metabolism gene expression levels in Oncomine, and found that the expression of several lipid metabolism genes (HMGCS2, DHRS2 and ACSL3) and PBX1 were significantly higher expression in ER1 breast cancer than in ERbreast cancer (Supporting Information Fig. 7) , consistent with our findings in tumor samples. The higher expression of several members of the LiMe gene set in ER-positive than in ER-negative tumors is consistent with an earlier report by Graham et al., 18 who also compared tumor to adjacent normal epithelium. Interestingly, they found that five LiMe genes (HMGCS2, HPGD, ALOX15B, UGT2B28 and SERHL) were also expressed more abundantly in normal epithelium adjacent to ER-positive tumors than in the ER-negative tumors and their adjacent normal epithelium. To the best of our knowledge, ours is the first report to describe converse gene expression patterns in morphologically normal breast tissues from the affected breast, compared to the contralateral breast. Our findings, juxtaposed to those of Graham et al. suggest that adjacent normal epithelium represents an area of field change where molecular profiles are similar to the tumor whereas the contralateral breast represents a breast environment that predates the development of the tumor. Many studies have compared molecular patterns in the tumor and adjacent normal tissue, some showing concordance and others not, with patterns that vary by specific genes. [36] [37] [38] However, comparisons between tumor and contralateral breast are sparse. 39 Additional insights will be provided by studies directed at genomes of the tumors and contralateral benign tissues, as well as studies of progression from normal through various proliferative lesions to cancer in our ongoing studies.
In summary, our study indicates that the differential expression of lipid metabolism-related genes in the benign breast may contribute to the development of different ER subtypes of breast cancer; and that significant differences exist between benign contralateral breast tissue and breast cancer. We propose that PBX1 is a prime candidate master regulator of this gene set and may have different functions in benign and malignant tissue, and in the presence or absence of ER. Thus, PBX1 functions as a pioneer factor in ERpositive cancer, while in benign high-risk breast tissue (i.e. the CUB), it is a putative risk factor for ER-negative cancer. Ongoing studies include the clinical validation of these genes as risk biomarkers for ER-negative breast cancer and the fuller definition of PBX1 function in ER-negative breast cells, both benign and malignant.
